Trial of BPI-572270 for advanced solid tumors with RAS mutations
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug, BPI-572270, for people with advanced solid tumors that have specific changes in the RAS gene. It may be an option if you have already tried standard treatments for your cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor with a RAS gene change confirmed by DNA testing.
- You have already received standard treatment for your type and stage of cancer.
- You are in good physical condition (ECOG score 0 or 1, meaning you are fully active or only slightly limited).
- Your major organs (like liver and kidneys) are working well.
- You do not have untreated or active brain tumors or metastases.
- You can swallow and absorb oral medications without major digestive issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.